Patent · US Active

Crystal form a of NHE3 inhibitor, preparation method therefor and application thereof

US12122762B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

SHENZHEN RENTAI PHARMATECH LTD. · CN

Inventors

Guobin Ren · Shanghai, CN
Dongxu Yi · Lo Wu, CN
Jiajun Huang · Longbeilingcun, CN

Key dates

Filing date	Sep 13, 2021
Grant date	Oct 22, 2024
Priority date	—
Expiry date	Jul 31, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is crystal form A of N,N′-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16, 18-tetrazohexahexane-1,26-di-yl)bis(4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl) benzene sulfonamide. The crystal form has good light stability, high-temperature stability, and high-humidity stability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.